NEW YORK, September 28, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Aegerion Pharmaceuticals, Inc. (NASDAQ:
AEGR), Align Technology, Inc. (NASDAQ: ALGN), Avalanche
Biotechnologies, Inc. (NASDAQ: AAVL), Agios Pharmaceuticals,
Inc. (NASDAQ: AGIO), Catalyst Pharmaceutical Partners,
Inc. (NASDAQ: CPRX). On Friday,
September 25, 2015, Nasdaq ended at 4686.50, down 1.01%, Dow
Jones advanced 0.70%, to finish the day at 16314.67, and the
S&P closed at 1931.34, down 0.05%. Register for your
complimentary reports at the links given below.
--
Aegerion Pharmaceuticals Inc
--
Aegerion Pharmaceuticals Inc's stock edged lower by 8.71% to
close Friday's session at USD 15.31.
The company's shares oscillated between USD
15.13 and USD 16.97, marking a new 52-week low during the
session. The stock recorded a trading volume of 0.71 million
shares, which was above its 50-day daily average volume of 0.56
million shares and below its 52-week average volume of 0.75 million
shares. Over the last three days, Aegerion Pharmaceuticals Inc's
shares have declined by 6.82% and in the past one week it has moved
down 13.01%. Furthermore, over the last three months, the stock has
lost 14.85% and in the past six months, the shares have shed 41.21.
The stock is at a price to book ratio of 2.92. The historical PB
ratio is near to 3.72. Additionally, the stock is trading at a
price to cash flow ratio of 25.09 and price to sales ratio of 2.00.
Sign up and read the free notes on AEGR at:
http://www.aciassociation.com/AEGR.pdf
--
Align Technology Inc
--
The stock of Align Technology Inc lost 0.54% to close Friday's
session at USD 56.65. The shares of
the company moved in the range of USD
55.91 and USD 57.79. A trading
volume of 0.70 million shares was recorded, which was lower than
its 150-day daily average volume of 0.79 million shares. Over the
last five days, Align Technology Inc's shares have declined by
1.34% while in the past one month, it has gained a momentum of
4.46%. Additionally, over the last three months, the stock has
declined 9.55% while in the past six months, the shares have
registered a profit of 4.83%. Further, the company is trading at a
price to earnings ratio of 31.83 and a price to book ratio of 5.89.
This compares to a historical PE ratio of 31.55. The historical PB
ratio is near to 5.96. Further, the stock is trading at a price to
cash flow ratio of 21.05 and price to sales ratio of 5.70. Register
for free on ACI Association and access the latest research on ALGN
at:
http://www.aciassociation.com/ALGN.pdf
--
Avalanche Biotechnologies Inc
--
Avalanche Biotechnologies Inc's stock decreased by 7.22% to
close Friday's session at USD 9.13.
The company's shares fluctuated in the range of USD 8.85 and USD
9.94 marking a new 52-week low during the session. A total
of 0.69 million shares exchanged hands, which surpassed its 50-day
daily average volume of 0.60 million shares and was above its
52-week average volume of 0.46 million shares. Over the last three
days Avalanche Biotechnologies Inc's shares have declined by
-10.23% and in the past one week it has moved down 18.77%.
Furthermore, over the last three months, the stock has lost 42.40%
and in the past six months, the shares have shed 76.35%. The
complete research on AAVL is available for free at:
http://www.aciassociation.com/AAVL.pdf
--
Agios Pharmaceuticals Inc
--
Agios Pharmaceuticals Inc's stock slipped by 5.76% to close
Friday's session at USD 80.79. The
company's shares oscillated between USD
78.52 and USD 88.27. The stock recorded a trading volume of
0.68 million shares, which was above its 50-day daily average
volume of 0.47 million shares and below its 52-week average volume
of 0.72 million shares. Over the last five days, Agios
Pharmaceuticals Inc's shares have declined by 17.46% and in the
past one month, it has lost 1.11%. In addition, over the last three
months, the stock has lost 23.49% and year to date, the shares have
shed 27.89%. The company has returned 26.71% in the past one year,
on a compounded total return basis. Free in-depth research on AGIO
is available at:
http://www.aciassociation.com/AGIO.pdf
--
Catalyst Pharmaceuticals Inc
--
Catalyst Pharmaceuticals Inc's stock declined 7.82% to close
Friday's session at USD 3.77. The
share price vacillated between USD 3.66 and
USD 4.16. The stock recorded a trading volume of 0.67
million shares, which was below its 50-day daily average volume of
0.71 million shares and below its 52-week average volume of 0.89
million shares. Over the last three days Catalyst Pharmaceuticals
Inc's shares have declined by 8.50% and in the past one week it has
moved down 14.90%. Moreover, in the last six months, the stock has
lost 10.02% while year to date, the shares have picked up 26.94%.
The stock is at a price to book ratio of 4.93. The historical PB
ratio is near to 5.82. The complimentary notes on CPRX can be
downloaded in PDF format at:
http://www.aciassociation.com/CPRX.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein. The information in this release has been
sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com